Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia
- PMID: 37980260
- DOI: 10.1016/j.vaccine.2023.11.015
Assessing the impact of chickenpox and shingles vaccination using intermittent enhanced surveillance in Queensland, Australia
Abstract
Introduction: Chickenpox and shingles are vaccine preventable diseases caused by varicella-zoster virus (VZV). Chickenpox is more common in children before adolescence and shingles among ≥50 years of age. With this study we aimed to determine changes in VZV epidemiology following chickenpox and shingles vaccine introduction in Queensland.
Methods: This case series study used notified cases of VZV infection in Queensland from January 2010 to December 2021. In Queensland, VZV notifications are received as mostly clinically unspecified cases from pathology laboratories. Intermittent enhanced surveillance was conducted using clinician follow up to determine chickenpox and shingles clinical presentation, and we then analysed these by age-group, time period, and within vaccine eligible cohorts.
Results: Of the 87,759 VZV notifications received, 70 % (n = 61,298) were notified as unspecified, followed by 23 % shingles (n = 19,927), and 7 % chickenpox (n = 6,534). Over the study period, the percent change in total notifications adjusted by age and sex was estimated to be an increase of 5.7 % (95 % CI 4.9-6.4) each year. The chickenpox notifications fell sharply at 18 months of age (eligible for chickenpox vaccine) with the rate being 57 % and 36 % lower among those aged 18-23 months compared to <12 and 12-17 months of age, respectively. Assuming all cases aged 60 years and older were shingles, notification rates of shingles decreased by 12-22 % among 70-79 years old (eligible for shingles vaccination) over the years 2017-2021 after vaccine introduction in 2016.
Conclusion: The VZV notification rate has increased over time in Queensland. Impact of chickenpox and shingles vaccines funded under National Immunisation Program is seen with a decline in notification rates among age-specific cohorts eligible to receive the vaccines under the program. Introduction of a second childhood dose chickenpox vaccine and more effective recombinant shingles vaccine may further improve the impact of the vaccination program.
Keywords: Chickenpox; Chickenpox vaccine; Shingles; Shingles vaccine; Varicella; Zoster.
Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Breaking the cycle: considerations for a life-course vaccination strategy against varicella-zoster virus.Expert Rev Vaccines. 2025 Dec;24(1):556-569. doi: 10.1080/14760584.2025.2514527. Epub 2025 Jun 19. Expert Rev Vaccines. 2025. PMID: 40511469 Review.
-
Vaccines for preventing herpes zoster in older adults.Cochrane Database Syst Rev. 2023 Oct 2;10(10):CD008858. doi: 10.1002/14651858.CD008858.pub5. Cochrane Database Syst Rev. 2023. PMID: 37781954 Free PMC article.
-
Vaccines for preventing herpes zoster in older adults.Cochrane Database Syst Rev. 2016 Mar 3;3(3):CD008858. doi: 10.1002/14651858.CD008858.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2019 Nov 7;2019(11). doi: 10.1002/14651858.CD008858.pub4. PMID: 26937872 Free PMC article. Updated.
-
Vaccines for preventing herpes zoster in older adults.Cochrane Database Syst Rev. 2012 Oct 17;10:CD008858. doi: 10.1002/14651858.CD008858.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2016 Mar 03;3:CD008858. doi: 10.1002/14651858.CD008858.pub3. PMID: 23076951 Updated.
-
Use of invitations and reminders are associated with higher levels of Herpes zoster (shingles) vaccination uptake. A cross-sectional survey of general practices in Wales, and ecological analysis of uptake data, 2022.Vaccine. 2024 Mar 7;42(7):1682-1689. doi: 10.1016/j.vaccine.2024.02.034. Epub 2024 Feb 14. Vaccine. 2024. PMID: 38360478
Cited by
-
Comparison of trend analysis of varicella zoster disease burden between China and the world 1990-2021 and disease burden forecast 2030.Front Public Health. 2025 Mar 10;13:1535977. doi: 10.3389/fpubh.2025.1535977. eCollection 2025. Front Public Health. 2025. PMID: 40129585 Free PMC article.
-
Evidence of Varicella Zoster Virus Reactivation in Children With Arterial Ischemic Stroke: Results of the VIPS II Study.J Am Heart Assoc. 2025 Mar 18;14(6):e039184. doi: 10.1161/JAHA.124.039184. Epub 2025 Mar 18. J Am Heart Assoc. 2025. PMID: 40099546 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical